The Wall Street Journal on Mythryl: “Replimune Group says FDA has approved its therapy for advanced skin…”

Replimune Group says FDA has approved its therapy for advanced skin cancer, ending a regulatory saga that spanned three submissions and two rejections and was a flashpoint in the tenure of the agency’s last commissioner. on.wsj.com/4wJPDUl

on.wsj.comFDA Approves Replimune’s Melanoma Drug On Third AttemptThe agency had turned down two earlier applications over clinical data-quality concerns.

6/8/26, 8:56 pm4 reposts6 likes

Post